{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Number of participants remain free of progression or death after ASCT","groups":[{"description":"Patients with refractory or relapsed myeloma received high-dose GemBuMel with ASCT","id":"OG000","title":"Gemcitabine/Busulfan/Melphalan"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From date of transplant until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Participants"}